Femtech Startup Raises £3M To Trial Menopause Hormone Patch
PRIVATEApr 05, 2023
Amount Raised
£3 Million
Round Type
Seed
CoventryHealth CareFashionLifestyle
Description
A startup that has developed a hormone patch for women with menopause symptoms has raised £3m to begin clinical trials.
Quick answer
Medherant raised £3 Million in a Seed round, dated April 5, 2023. Medherant is based in Coventry, England, United Kingdom.
How much did Medherant raise?
Medherant raised £3 Million in a Seed round on April 5, 2023.
What does Medherant do?
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists.
Where is Medherant based and how big is it?
Medherant is based in Coventry, England, United Kingdom.
Who are the decision-makers at Medherant?
Fundz holds 1 contact at Medherant. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Fashion and Lifestyle around the same time
Companies in the same sectors as Medherant that raised within 45 days of this round, from Fundz verified event records.
The Ayurveda Co raised $13M (Funding Round) on March 13, 2023.
Rennaï raised an undisclosed amount on May 10, 2023.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Medherant
Location
Coventry, England, United Kingdom
About
Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry.
The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile.
The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal.
Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Medherant raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CoventryHealth CareFashionLifestyle